- 1 Relationships of Prescription Opioid Sales to Opiate Treatment Admissions and Overdose
- 2 Deaths: A Reanalysis of Relationships -- United States 2010-2019
- 3
- 4 Larry Aubry and B. Thomas Carr
- 5 Corresponding Author:
- 6 B. Thomas Carr
- 7 Carr Consulting
- 8 1215 Washington Avenue
- 9 Suite 201
- 10 Wilmette, IL 60091 USA
- 11 Email: Tom.Carr@CarrConsulting.net
- 12

## 13 Relationships of Prescription Opioid Sales to Opiate Treatment Admissions and Overdose

# 14 Deaths: A Reanalysis of Relationships -- United States 2010-2019

- 15 Larry Aubry and B. Thomas Carr
- 16

# 17 ABSTRACT

18

19 Background: In 2016, the United States Centers for Disease Control and Prevention (CDC) issued "CDC Guideline for Prescribing Opioids for Chronic Pain". The guideline used 20 data from 1999 to 2010 that related Opioid Sales to Opiate Treatment Admissions (a measure 21 22 of drug addiction rates) Opioid Deaths. The CDC's analysis indicated that opioid prescriptions are directly correlated<sup>1-8</sup> with drug addiction and overdose mortality outcomes. As a result, 23 24 prescription opioid sales have been curtailed, making it difficult for sufferers of severe chronic pain to access an effective treatment option. In this paper, the relationships between opioid 25 26 sales, drug addiction, and opioid deaths are reexamined using data from 2010 to 2019.

Methods: Linear regression models were fit to each response separately. Opioid sales (measured as MME per capita) was the independent variable. Total overdose deaths (TOD), any opioid overdose deaths (AOD), prescription opioid overdose deaths (POD) and opiate treatment admissions (OTA) were the dependent, response variables. The models were assessed using three criteria: the statistical significance of the model (Overall P-Value), the quality of the fit (R<sup>2</sup>), and the sign of the slope coefficient.

Results: The analyses revealed that the direct correlations (significant, positive slopes) reported by the CDC based on data from 1999 to 2010 no longer exist based on data from 2010 to 2019. The relationships either have reversed (i.e., significant negative slopes) or are nonexistent (no significant model).

37 Conclusions: The basis for the CDC guideline no longer holds. The guideline should 38 be updated or annulled based on the current relationships that have existed for a decade. This 39 is especially relevant for people suffering from severe, chronic pain, whose access to 40 prescription opioids has been severely curtailed under the current guideline and to ensure that 41 government resources are directed to an effective approach to reducing overdose deaths. 42

# 43 BACKGROUND AND RATIONALE

44

In 2015, the U.S. Department of Health and Human Services (HHS) declared "There is a
clear correlation between opioid prescribing rates and overdose death rates in the United

States."9 Direct correlations that existed between Total Overdose Deaths (TOD). Any Opioid 47 48 Deaths (AOD), Prescription Opioid Deaths (POD), Opiate Treatment Admissions (OTA) and 49 prescription opioid sales (POS) from 1999-2010 (see Figure 1) led the CDC to conclude that prescribed opioids are the determinant for overdose deaths and opiate/opioid treatment 50 admissions.<sup>1-8</sup> Since the 2016 "CDC Guideline for Prescribing Opioids for Chronic Pain" 51 (quideline), cutting prescription opioid sales has been CDC's, DEA's, legislative policy makers', 52 and practitioners' solution to cut overdose deaths and opiate treatment admissions.<sup>10-12</sup> 53 54 \*\*\* Place Figure 1 Approximately Here \*\*\* 55 56 The impact of the CDC guideline has been systemic. Long term opioid therapy patients are not 57 accepted as new patients by over 40% of primary pain clinics.<sup>12</sup> Projected cuts to opioid Rx 58

59 MME per capita will result in 2020 values falling close to levels prescribed in 2000 of 298<sup>13</sup> while 60 the over 55 population has increased by 40 million. The American Medical Association (AMA) 61 reports "the CDC Guideline has harmed patients"<sup>14</sup>, "72% of pain medicine specialists said that 62 they—or their patients—have been required to reduce the quantity or dose of medication they 63 have prescribed"<sup>14</sup> as a result of the guideline.

"Almost 18 million Americans are currently taking long-term prescription opioids"<sup>15</sup> to 64 treat chronic pain. A "Health and Human Services Pain Management Best Practices Inter-65 Agency Task Force has determined that tens of millions of Americans rely on legal prescription 66 opioids to treat acute or severe chronic pain, including pain arising from cancer as well as 67 terminal or degenerative illnesses. The Food and Drug Administration (FDA) long ago approved 68 opioid medications for these purposes, and doctors throughout the country lawfully prescribe 69 them."<sup>16</sup> 92% of physicians and patients believe that opioids reduce pain and 57% report better 70 guality of life.17 71

72

With drug overdose deaths "growing, inexorably and exponentially, for four decades"<sup>18</sup> to a record 93,000 in 2020; FY2019 federal funding to combat the opioid crisis increasing to a record \$7.6 billion<sup>19</sup> and "drug overdoses are now costing the United States approximately \$1 trillion annually",<sup>20</sup> it is critical that public health policy guidance not be based on out-of-date and/or misleading information.

78

The present paper updates correlations between POS to OTA, POD, AOD and TOD from 2010 to 2019 and shows that the direct relationships that existed from 1999 to 2010 are no

81	longer present in fact, in some instances the relationships have reversed. Consequently, we
82	find that continuing the policies of cutting prescription opioid sales to reduce TOD, AOD, POD,
83	and OTA is unfounded.
84	
85	METHODS:
86	
87	DESCRIPTION OF DATA SOURCES:
88	
89	Data Limitations: The authors acknowledge that the data reported by CDC and other
90	sources necessarily contains inaccuracies. It is widely understood that it is impossible to
91	ascertain the specific cause of an overdose death in all cases. This may be due, for example, to
92	poly drug use with alcohol, and an inability to reliably determine the source of opioids detected
93	in postmortem blood toxicity screens (e.g., prescription vs. illicit), among other confounding
94	issues. <sup>,21,22</sup> However, the authors have employed the same data sources that CDC guideline
95	appears to be based upon. As such, the results of analyses presented here are at least as
96	reliable as what the CDC would be able to obtain from their own analyses, if they chose to
97	undertake them. Thus, the following sources have been applied.
98	
99	Drug Overdose Deaths (National); Total Overdose Deaths, Any Opioid Overdose
100	Deaths and Prescription Opioid Overdose Deaths <sup>23</sup> : 1999-2019 data accessed from
101	Drugabuse.gov., Published 2021. Accessed January 10, 2021 from
102	https://www.drugabuse.gov/sites/default/files/Overdose_data_1999-2019.xlsx
103	
104	Opioid Overdose Death Crude Rates (U.S. States) <sup>24</sup> : 1999-2019 data accessed from
105	CDC, National Center for Health Statistics. Underlying Cause of Death, 1999-2019 were
106	sourced from CDC WONDER Online Database, released in 2020. Data are from the Multiple
107	Cause of Death Files, 1999-2019, as compiled from data provided by 57 vital statistics
108	jurisdictions through the Vital Statistics Cooperative Program. Identified using underlying cause-
109	of-death codes X40–X44, X60–X64, X85, and Y10–Y14. Accessed Feb 7, 2021, 12:01:39 PM
110	from http://wonder.cdc.gov/ucd-icd10.html
111	
112	Opiate/Opioid Treatment Admissions (National) <sup>25</sup> : 2006-2008 data accessed
113	from Substance Abuse and Mental Health Services Administration, Center for Behavioral Health
114	Statistics and Quality, "Treatment Episode Data Set (TEDS): 2000-2010". National Admissions

115	to Substance Abuse Treatment Services. DASIS Series S-61, HHS Publication No. (SMA) 12-
116	4701. Rockville, MD: Substance Abuse and Mental Health Services Administration
117	(samhsa.gov), 2012. p.43. Accessed April 18, 2021 from <u>Treatment Episode Data Set (TEDS)</u>
118	<u>2000 - 2010 (samhsa.gov)</u>
119	
120	Opiate/Opioid Treatment Admissions (National) <sup>26</sup> : 2008-2018 data accessed from
121	Substance Abuse and Mental Health Services Administration, Center for Behavioral Health
122	Statistics and Quality, "Treatment Episode Data Set (TEDS): 2018."
123	Admissions to and Discharges from Publicly Funded Substance Use Treatment. Rockville, MD:
124	2018 TEDS Annual Report. Substance Abuse and Mental Health Services Administration
125	(samhsa.gov), 2020. Table 1.1a. Accessed April 18, 2021 from
126	https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018 TEDS/2018 TEDS.html#
127	PSU. 2018 TEDS Annual Report (samhsa.gov)
128	
129	Opioid Prescribing; MME per Capita (National) <sup>27</sup> : 2006-2013 data accessed from
130	CDC," Annual Surveillance Report of Drug-Related Risks and Outcomes — United States
131	Surveillance Special Report".2019 CDC, U.S. Department of Health and Human Services.
132	Published November 1, 2019. p.115. Accessed January 10, 2021 from
133	https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf
134	
135	Opioid Prescribing; MME per Capita (National) <sup>28</sup> : 2014-2018 data accessed from
136	Statista," Annual morphine milligram equivalents (MME) dispensed per capita in the U.S. from
137	2014 to 2018", MME per capita U.S. 2014-2018. Statista. May 28, 2021. Accessed July 8, 2021
138	from https://www.statista.com/statistics/753284/number-of-mme-dispensed-per-capita-in-us/.
139	
140	Opioid Prescribing; MME per Capita (National) <sup>29</sup> : 2019 data accessed from The
141	IQVIA Institute, "Prescription Opioid Trends in the United States", Institute Report, Dec 16,
142	2020. p.4. Accessed January 10, 2021 from https://www.iqvia.com/insights/the-iqvia-
143	institute/reports/prescription-opioid-trends-in-the-united-states.
144	
145	Opioid Prescribing; Opioid Dispensing Rates per 100 (U.S. States) <sup>30</sup> :
146	2006-2019 data accessed from CDC, "U.S. Opioid Dispensing Rate Maps, Drug Overdose",
147	CDC Injury Center. Accessed February 9, 2021 from https://www.cdc.gov/drugoverdose/rxrate-

### 148 <u>maps/index.html</u>

149

Opioid Sales kg/10,000 (National): For the period from 2006 through 2018/2019, these
data were not known to be publicly available. We instead examined Opioid Prescribing by
separately computing MME per Capita.

153

# 154 STATISTICAL METHODOLOGY:

155

Objective 1: Evaluate MME per Capita as a legitimate alternative measure of 156 Annual Prescription Opioid Sales: The CDC used Annual Prescription Opioid Sales to 157 support their current guideline (Figure 1). Data on Annual Prescription Opioid Sales are not 158 readily available since 2010. However, MME per Capita data are available from 2006 to 2019 159 and offer a reasonable surrogate. Annual Sales data from the CDC chart were visually extracted 160 161 and correlated with MME per Capita data, using simple linear regression analysis. The goal of 162 the analysis was to evaluate MME per Capita as a legitimate alternative measure of Annual Prescription Opioid Sales. 163

164

165 Objective 2: Assess the strength and nature of the relationships between total 166 overdose deaths (TOD), any opioid overdose deaths (AOD), prescription opioid overdose 167 deaths (POD) and opiate treatment admissions (OTA) and Opioid Sales/MME per Capita: Consistent with the methods used by the CDC, simple linear regression models were fit to the 168 data. Separate models were fit to each of the four dependent variables (TOD, AOD, POD, and 169 OTA) using Annual Opioid Sales (i.e., MME per Capita) as the independent variable. Two 170 models were fit to each dependent variable. One model covered the years presented in the 171 original CDC chart (for which MME per Capita data were available) (2006-2010) and the second 172 model covered the years since the published CDC chart (2010-2019). 173 174 For both objectives, the strength and nature of relationships in all the regression models were 175 assessed using three criteria: 176 177

178 1) significance of the regression model (overall P-Value),

- 179
- 180 2) the quality of the model's fit  $(R^2)$ , and
- 181

182	3) the sign of the linear slope coefficient (+ or -).
183	
184	All models were fit using PROC REG from SAS/STAT software Version 9.4.
185	
186	RESULTS AND DISCUSSION
187	
188	Data from CDC's original chart was reconstructed using graphical analysis. The
189	reconstructed Annual Prescription Opioid Sales values from the original CDC chart are highly
190	correlated with publicly available MME per Capita values ( $R^2 = 94\%$ ), which are available for
191	more recent years than the sales data used by the CDC. MME per Capita is thus used in place
192	of Annual Prescription Opioid Sales for all subsequent analyses.
193	
194	For the years covered in the CDC's original chart (for which MME per Capita data are
195	available, i.e., 2006-2010), the CDC's claim of positive/direct relationships between TOD, AOD,
196	POD, and OTA and Annual Prescription Opioid Sales (i.e., MME per Capita) were validated
197	(91% < $R^2$ < 97%), with statistically significant, positive slopes.
198	
199	For more recent years (i.e., 2010-2019), however, the CDC's assertion of continued
200	direct relationships is not valid. The relationships between TOD, AOD, POD, and OTA and
201	Annual Prescription Opioid Sales (i.e., MME per Capita) are either non-existent or significantly
202	negative/inverse (Figures 2 and 3).
203	
204	*** Place Figure 2 Approximately Here ***
205	
206	*** Place Figure 3 Approximately Here ***
207	
208	National trends since 2010 are paralleled in a strong majority of states. Between 2010
209	and 2019 inclusive, there was a statistically significant negative correlation (95% confidence
210	level) between AOD and Annual Prescription Opioid Sales in 40 states, with significant positive
211	correlations occurring in only 2 states. Eight (8) states did not exhibit a significant (95%
212	confidence level) relationship between overdose deaths and prescription opioid sales during the
213	2010-2019 time period.
214	

215 Results for all regression models are presented in Table 1.

216	
217	*** Place Table 1 Approximately Here ***
218	
219	CONCLUSIONS:
220	
221	Starting in 2010 opioid MME per Capita (POS) does not have a "clear correlation" <sup>9</sup> or
222	move "in parallel" <sup>3</sup> or "in lockstep" <sup>2</sup> with OTA, POD, AOD or TOD. The relationship changed
223	from direct to inverse.
224	
225	From a peak in 2010 to 2019, POS decreased by over 50%. If POS were the root cause,
226	correlated to and resulted in "parallel" or "lockstep" movements in POD, AOD, OTA, and TOD,
227	then the result should have been an equivalent percentage reduction in these metrics. From
228	2010 to 2019, POD should have been 6,800 in 2019 instead of ending the decade flat at 14,139;
229	AOD should have been 9,900 instead of increasing by 2.5x to 49,860; OTA should have been
230	less than 210,000 in 2018 instead of increasing by 1.6x to 650,212 and TOD should be 17,900
231	instead of doubling to 70,630.
232	
233	Data from the National Health Interview Survey (NHIS) demonstrate that between 2011
234	to 2016, while MME per capita declined by 21.8%, the amount of pain reported by Americans
235	significantly increased. Incidence of high impact chronic pain increased by 84.9%, from 4.8
236	percent (10.6 million people, 1 in 20) <sup>31</sup> to 8.0% of U.S. adults (19.6 million, 1 in $12.5$ ) <sup>32</sup> .
237	Incidence of patients afflicted with chronic pain increased by 67.2% from 13.6 percent (29.9
238	million, 1 in 7.4) <sup>31</sup> to 20.4% (50.0 million, 1 in 5) <sup>32</sup> of the U.S. adult population.
239	
240	In light of the evidence presented in this paper, it should be recognized that the basis for
241	the 2016 guideline is no longer valid. The guideline and associated content should be updated
242	or annulled based on the current relationships that have existed for a decade, to eliminate the
243	unnecessary suffering of individuals with chronic pain and to avoid the wasteful and ineffective
244	spending patterns the government is executing based on the out-of-date guideline.
245	
246	Source of Funding: None.
247	
248	Author Disclosures: The authors report no relationship or financial interest with any entity that
249	would pose a conflict of interest concerning the subject matter of this paper.

250	
251	References:
252	1. CDC Press Releases. (2016, January 1). CDC.
253	https://www.cdc.gov/media/releases/2016/p0315-prescribing-opioids-guidelines.html
254	
255	2. NCIPC Board of Scientific Counselors. "Draft Meeting Minutes" Department of Health
256	and Human Services Public Health Service Board of Scientific Counselors (BSC), Centers for
257	Disease Control and Prevention (CDC), National Center for Injury Prevention and Control
258	(NCIPC) Eighteenth Meeting: Thursday, January 28, 2016: p.9.
259	https://www.cdc.gov/injury/pdfs/bsc/NCIPC_BSC_01_28_2016_Minutes_Final_3_15_2016.pdf
260	
261	3. CDC Guideline for Prescribing Opioids for Chronic Pain -United States, 2016 Morbidity
262	and Mortality Weekly Report. (2016): p.2.
263	https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6501e1.pdf
264	
265	4. Vital Signs: Overdoses of Prescription Opioid Pain Relievers United States, 1999
266	2008. Published 2019. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm
267	
268	5. Haegerich, T. (2018). The Opioid Overdose Epidemic in the United States NCIPC/CDC
269	Research Priorities: p.34. https://www.cdc.gov/injury/pdfs/bsc/Opioid-Research-
270	Priorities BSCJune2018 Haegerich-a.pdf
271	
272	6. Noonan, R. (2016). Understanding and Addressing the Opioid Crisis Nevada's
273	Prescription Drug Abuse Summit CDC PERSPECTIVE: p.8.
274	https://dpbh.nv.gov/uploadedFiles/dpbh.nv.gov/content/Programs/ClinicalSAPTA/Meetings/5%2
275	0%20Rise%20of%20Heroin%20Rita%20Noonan.pdf
276	
277	7. Kolodny, A. (n.d.). Statement by:p.1,2.
278	https://docs.house.gov/meetings/IF/IF14/20180228/106915/HHRG-115-IF14-Wstate-KolodnyA-
279	20180228.pdf
280	
281	8. Bacon S. CDC's Approach to Addressing the Opioid Overdose Epidemic.; 2016: p.7.
282	https://www.ncsl.org/portals/1/documents/health/InjuryMtg2016_SBacon.pdf
283	

284	9. ASPE ISSUE BRIEF.; 2015. Accessed January 25, 2022: p.5.
285	https://aspe.hhs.gov/sites/default/files/migrated_legacy_files/56406/ib_OpioidInitiative.pdf
286	
287	10. Dasgupta, N., Beletsky, L., & Ciccarone, D. (2018). Opioid Crisis: No Easy Fix to Its
288	Social and Economic Determinants. American journal of public health, 108(2), 182–186.
289	https://doi.org/10.2105/AJPH.2017.304187
290	
291	11. Chen, Q., Larochelle, M. R., Weaver, D. T., Lietz, A. P., Mueller, P. P., Mercaldo, S.,
292	Wakeman, S. E., Freedberg, K. A., Raphel, T. J., Knudsen, A. B., Pandharipande, P. V., &
293	Chhatwal, J. (2019). Prevention of Prescription Opioid Misuse and Projected Overdose Deaths
294	in the United States. JAMA network open, 2(2), e187621.
295	https://doi.org/10.1001/jamanetworkopen.2018.7621
296	
297	<b>12.</b> Lagisetty, P., et al. Improving Access to Primary and Pain Care for Patients Taking
298	Opioids for Chronic Pain in Michigan: Recommendations from an Expert Panel. (2021): p.3.
299	https://doi.org/10.7302/1699
300	
301	13. IQVIA, "Prescription Opioid Trends in the United States. Measuring and
302	understanding progress in the opioid crisis." Institute Report. Dec 16, 2020. Accessed
303	August 26, 2021. https://www.iqvia.com/en/insights/the-iqvia-
304	institute/reports/prescription-opioid-trends-in-the-united-states
305	
306	14. Majara, J.L. Docket No. CDC-2020-0029 Letter Dowell D, Dowell.; 2020. p.5,7
307 308	https://searchlf.ama- assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2F
309	LETTERS%2F2020-6-16-Letter-to-Dowell-re-Opioid-Rx-Guideline.pdf
310	
311	<b>15.</b> Beth D Darnall, PhD, David Juurlink, MD, PhD, FRCPC, FAACT, FACMT, Robert D
312	Kerns, PhD, Sean Mackey, MD, PhD, Brent Van Dorsten, PhD, Keith Humphreys, PhD, Julio A
313	Gonzalez-Sotomayor, MD, Andrea Furlan, MD, PhD, Adam J Gordon, MD, MPH, FACP,
314	DFASAM, CMRO, Debra B Gordon, RN, DNP, FAAN, Diane E Hoffman, JD, MS, Joel Katz,
315	PhD, CPsych, FCAHS, Stefan G Kertesz, MD, MSc, Sally Satel, MD, Richard A Lawhern, PhD,
316	Kate M Nicholson, JD, Rosemary C Polomano, PhD, RN, FAAN, Owen D Williamson,
317	FFPMANZCA, FRCSC Pain Medicine, Heath McAnally, MD, MSPH, Ming-Chih Kao, PhD, MD,

318 CIPS, Stephan Schug, MD, FANZCA, FFPMANZCA, EDPM, Robert Twillman, PhD, FACLP. 319 Terri A Lewis, PhD, NCC, Richard L Stieg, MD, MHS, Kate Lorig, DrPH, Theresa Mallick-Searle, 320 MS, APRN, Robert W West, PhD, Sarah Gray, PsyD, Steven R Ariens, RPh, PD, Jennifer Sharpe Potter, PhD, MPH, Penney Cowan, Chad D Kollas, MD, FACP, FAAHPM, Danial Laird, 321 MD, JD, Barby Ingle, J Julian Grove, MD, Marian Wilson, PhD, MPH, RN-BC, Kashelle 322 Lockman, PharmD, MA, Fiona Hodson, RN, DipAPPSci, Carol S Palackdharry, MD, MS, FACP, 323 324 Roger B Fillingim, PhD, Jeffrey Fudin, PharmD, DAIPM, FCCP, FASH, FFSMB, Jennifer Barnhouse, Aiav Manhapra, MD, Steven R Henson, MD, Bruce Singer, PhD, Marie Liosenvoor, 325 326 PharmD, Marlisa Griffith, RN, Jason N Doctor, PhD, Kimeron Hardin, PhD, ABPP, FACHP, 327 Cathleen London, MD, Jon Mankowski, CA, LCSW, Andrea Anderson, Linda Ellsworth, FNP-C, Lisa Davis Budzinski, Becky Brandt, RN, Greg Hartley, PT, DPT, Debbie Nickels Heck, MD, 328 Mark J Zobrosky, Celeste Cheek, PT, DPT, Megan Wilson, Cynthia E Laux, RN, Geralvn Datz. 329 PhD, Justin Dunaway, PT, DPT, Eileen Schonfeld, RN, Chaplain, Melissa Cady, DO, Thérèse 330 331 LeDantec-Boswell, Meredith Craigie, MD, FFPMANZCA, FANZCA, John Sturgeon, PhD, Pamela Flood, MD, Melita Giummarra, PhD, Jessica Whelan, MSN, FPMHNP-BC, Beverly E 332 Thorn, PhD, Richard L Martin, Michael E Schatman, PhD, Maurice D Gregory, MD, Joshua Kirz, 333 334 PhD, Patti Robinson, PhD, James G Marx, MD, FASAM, Jessica R Stewart, Phillip S Keck, 335 PhD, LCP, Scott E Hadland, MD, MPH, MS, Jennifer L Murphy, PhD, Mark A Lumley, PhD, 336 Kathleen S Brown, PhD. Michael S Leong, MD. Mechele Fillman, MSN, NP. James W Broatch. 337 MSW, Aaron Perez, PT, Kristine Watford, MD, Kari Kruska, RN (Retired), Dokyoung Sophia 338 You, PhD, RN, Stacy Ogbeide, PsyD, MS, ABPP, Amy Kukucka, MSN, APRN, CHPN, FNP-C, 339 Susan Lawson, PhD, LCSW, James B Ray, PharmD, CPE, T Wade Martin, MD, James B Lakehomer, PhD, Anne Burke, MPsych (clin), Dip Clin Hyp, Robert I Cohen, MD, MA, Peter 340 Grinspoon, MD, Marc S Rubenstein, PT, DPT, Cert-APHPT, Stephani Sutherland, PhD 341 (Neuroscience), Kristie Walters, RN (Retired), Travis Lovejoy, PhD, MPH, 342 "International Stakeholder Community of Pain Experts and Leaders Call for an Urgent Action on 343 Forced Opioid Tapering," Pain Medicine, Volume 20, Issue 3, March 2019, Pages 429-344 433, <u>https://doi.org/10.10</u>93/pm/pnv228 345 346 347 16. Walmart Inc., Plaintiff, v. U.S. Department of Justice; Attorney General William P. Barr; U.S. Drug Enforcement Administration; Acting Administrator Timothy J. Shea, Defendants. Case 348 4:20-cv-00817 Document 1 Filed 10/22/20. https://corporate.walmart.com/media-349 library/document/walmart-v-doj-dea-complaint/ proxyDocument?id=00000175-522e-dbe2-a9fd-350

351 7f6e94120000

353	17. Manchikanti, L., Kaye, A. M., Knezevic, N. N., McAnally, H., Slavin, K., Trescot, A. M.,								
354	Blank, S., Pampati, V., Abdi, S., Grider, J. S., Kaye, A. D., Manchikanti, K. N., Cordner, H.,								
355	Gharibo, C. G., Harned, M. E., Albers, S. L., Atluri, S., Aydin, S. M., Bakshi, S., & Barkin, R. L.								
356	(2017). Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain:								
357	American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician, 20(2S),								
358	S3–S92. https://pubmed.ncbi.nlm.nih.gov/28226332/								
359									
360	<b>18.</b> Guzman, A. (n.d.). The Opioid Epidemic and the Practice of Medicine:p.12,13.								
361	https://www.deadiversion.usdoj.gov/mtgs/pract_awareness/conf_2019/dec_2019/guzman.pdf								
362									
363	<b>19.</b> Tracking FY2019 Federal Funding to Combat the Opioid Crisis   Bipartisan Policy								
364	Center. (n.d.). Bipartisanpolicy.org. https://bipartisanpolicy.org/report/combating-the-opioid-								
365	<u>crisis-2020/</u>								
366									
367	20. Commission on Combating Synthetic Opioid Trafficking. Commission on Combating								
368	Synthetic Opioid Trafficking: Final Report. Reports from the Commission on Combating								
369	Synthetic Opioid Trafficking (2022). Published online February 8, 2022. p.9								
370	https://www.rand.org/pubs/external_publications/EP68838.html.								
274	21 Dennin I.F. & Colomon I. I. (2021) CDC's Efforts to Quantify Dressvintian Onisid								
371	<b>21.</b> Peppin, J. F., & Coleman, J. J. (2021). CDC's Efforts to Quantify Prescription Opioid								
372	Overdose Deaths Fall Short. Pain and therapy, 10(1), 25–38. <u>https://doi.org/10.1007/s40122-</u>								
373	<u>021-00254-z</u>								
374									
375	22. Seth, P., Rudd, R. A., Noonan, R. K., & Haegerich, T. M. (2018). Quantifying the								
376	Epidemic of Prescription Opioid Overdose Deaths. American journal of public health, 108(4),								
377	500–502. <u>https://doi.org/10.2105/AJPH.2017.304265</u>								
378									
379	<b>23.</b> (2021). Drugabuse.gov.								
380	https://www.drugabuse.gov/sites/default/files/Overdose_data_1999-2019.xlsx								
381									
382	24. Underlying Cause of Death, 1999-2019 Request. Cdc.gov. Published 2017.								
383	https://wonder.cdc.gov/ucd-icd10.html								
384									

385	<b>25.</b> Treatment Episode Data Set (TEDS) 2000 -2010 National Admissions to Substance							
386	Abuse Treatment Services. (n.d.). Retrieved December 17, 2021, from							
387	https://www.samhsa.gov/data/sites/default/files/2010_Treatment_Episode_Data_Set_National/2							
388	010 Treatment Episode Data Set National.pdf							
389								
390	26. 2018 TEDS Annual Report. www.samhsa.gov. Accessed December 17, 2021.							
391	https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018 TEDS/2018 TEDS.html#							
392	<u>PSU</u> .							
393								
394	27. ANNUAL SURVEILLANCE REPORT OF DRUG-RELATED RISKS AND OUTCOMES.							
395	(2019). https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf							
396								
397	28. MME per capita U.S. 2014-2018   Statista. (n.d.). Statista.							
398	https://www.statista.com/statistics/753284/number-of-mme-dispensed-per-capita-in-us/							
399								
400	29. Prescription Opioid Trends in the United States. www.iqvia.com.							
401	https://www.iqvia.com/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-							
402	states							
403								
404	<b>30.</b> U.S. Opioid Dispensing Rate Maps   Drug Overdose   CDC Injury Center. (2021, June							
405	23). Www.cdc.gov. https://www.cdc.gov/drugoverdose/rxrate-maps/index.html							
406								
407	31. Prevalence and Profile of High Impact Chronic Pain." NCCIH.							
408	https://www.nccih.nih.gov/research/research-results/prevalence-and-profile-of-high-							
409	impact-chronic-pain							
410								
411	<b>32.</b> Dahlhamer J, Lucas J, Zelaya, C, et al. Prevalence of Chronic Pain and High-							
412	Impact Chronic Pain Among Adults — United States, 2016. MMWR Morbidity and							
413	Mortality Weekly Report. 2018;67(36):1001-1006.							
414	DOI: http://dx.doi.org/10.15585/mmwr.mm6736a2external icon							
415 416								
416 417								

## 418

Dependent Variable	Independent Variable	Years	Related Figure	n	R <sup>2</sup>	P-Value	Slope	95% LCL	95%UCL	Interpretation
MME per Capita	Total Annual Prescription Opioid Sales	2006-2010	NA	5	0.94	0.006	141	76	206	Strong Model. Significant, Positive Relationship.
Total Overdose Deaths	MME per Capita	2006-2010	NA	5	0.97	0.002	20	14	26	Strong Model. Significant, Positive Relationship.
Any Opioid Overdose Deaths	MME per Capita	2006-2010	NA	5	0.99	0.000	20	17	24	Strong Model. Significant, Positive Relationship.
Prescription Opioid Deaths	MME per Capita	2006-2010	NA	5	0.97	0.002	15	10	20	Strong Model. Significant, Positive Relationship.
Opioid Treatment Admissions/1000	MME per Capita	2006-2010	NA	5	0.91	0.011	0.60	0.26	0.94	Strong Model. Significant, Positive Relationship.
Total Overdose Deaths	MME per Capita	2010-2019	Figure 3	10	0.89	0.000	-85	-109	-61	Strong Model. Significant, Negative Relationship.
Any Opioid Overdose Deaths	MME per Capita	2010-2019	Figure 3	10	0.92	0.000	-76	-95	-57	Strong Model. Significant, Negative Relationship.
Prescription Opioid Deaths	MME per Capita	2010-2019	Figure 3	10	0.03	0.615	-1.4	-7.4	4.7	No Model. Nonsignificant Relationship
Opioid Treatment Admissions/1000	MME per Capita	2010-2018	Figure 3	9	0.89	0.000	-0.64	-0.84	-0.43	Strong Model. Significant, Negative Relationship.

#### Table A1: Summary of Regression Models Fit in the Paper

421	Captions for Figures
422	
423	Figure 1: CDC Chart 1999-2010, February 28, 2018, Congressional testimony "Combatting the
424	Opioid Crisis." made before the Committee on Energy & Commerce, Subcommittee on Health
425	U.S. House of Representatives: "The CDC has shown that a sharp increase in prescriptions for
426	opioids <u>resulted</u> in a corresponding rise in addiction and overdose deaths. This is a CDC graph.
427	The green line represents opioid prescribing, the red line represents opioid deaths, and the blue
428	line represents opioid addiction. The green line went up as opioid prescriptions started to soar, it
429	led to parallel increases in addiction and overdose deaths."7
430	
431	Figure 2: 2010-2019 Update: The green line represents opioid prescribing (POS, MME/capita);
432	the red lines are opioid deaths (POD, AOD & TOD); the blue line represents opioid addiction
433	(OTA). Over the past decade, as the green line (prescription opioids) declined by +50%,
434	prescription opioid deaths remained flat while opioid addiction, any opioid and total overdose
435	deaths continued increasing "exponentially" <sup>8</sup> .
436	
437	Figure 3: 2010-2019 Regression Models: Illustrates the regression of OTA, POD, AOD and
438	TOD as functions of POS. Significant, negative relationships were found for OTA, AOD, and
439	TOD. No significant relationship exists between POD and POS.

# 441 Figure 1





Figure 2 443



#### Figure 3 446

